Key factors
sym | EYPT |
exch | US |
MCap | 1.140B |
Beta | 1.68 |
EPS | -1.82 |
Div date | 0000-00-00 |
Yesterday
sym | EYPT |
exch | US |
close | 17.57 |
50 Day MA | 24.83 |
200 Day MA | 15.63 |
52 Week High | 30.99 |
52 Week Low | 4.22 |
Target Price | 43.67 |
Market Cap Mln | 1140.63 |
Share statistics
Shares Outstanding | 49.83M |
Shares Float | 30.76M |
Percent Institutions | 104.03 |
PercentInsiders | 1.022 |
SharesShort | 6845.4K |
Short Ratio | 5.85 |
Shares Short Prior Month | 6579.35K |
Short Percent | 18.00 |
Income
Revenue TTM | 46.01M |
Revenue Per Share TTM | 1.183 |
Quarterly Revenue Growth YOY | 33.19 |
Gross Profit TTM | 26.94M |
EBITDA | -73.4M |
Diluted Eps TTM | -1.82 |
earning
Operating Margin TTM | -1.08 |
EPS Estimate Current Quarter | -0.49 |
EPS Estimate Current Year | -1.94 |
EPS Estimate Next Quarter | -0.44 |
EPS Estimate Next Year | -2.53 |
Earnings Share | -1.82 |
Dividend
Dividend Date | 2020-12-09 |
Last Split Date | 2020-12-09 |
Last Split Factor | 1:10 |
business
Enterprise Value Ebitda | -11.8 |
Enterprise Value Revenue | 17.73 |
Book Value /share | 5.43 |
Price Book MRQ | 4.288 |
Price Sales TTM | 24.78 |
ProfitMargin | -1.53 |
ReturnOnAssetsTTM | -0.17 |
ReturnOnEquityTTM | -0.39 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Pharmaceuticals |
Gic Sector | Health Care |
Gic Sub Industry | Pharmaceuticals |
Industry | Biotechnology |
Sector | Healthcare |
Codes
ISIN | US30233G2093 |
CIK | 1314102 |
Code | EYPT |
CUSIP | 74439M107 |
Employer Id Number | 26-2774444 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-04-12 |
Home Category | Domestic |
info
Fiscal Year End | December |
Full Time Employees | 121.0 |
IPODate | 2005-01-27 |
International Domestic | International Domestic |
MostRecent Quarter | 2023-12-31 |
Contact
Name | Eyepoint Pharmaceuticals Inc |
Address | 480 Pleasant Street, Watertown, MA, United States, 02472 |
Country Name | USA |
Phone | 617 926 5000 |
Web URL | https://eyepointpharma.com |
Logo URL | /img/logos/US/EYPT.png |
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.